| 前收盘价格 | 7.05 |
| 收盘价格 | 7.18 |
| 成交量 | 70,889 |
| 平均成交量 (3个月) | 87,689 |
| 市值 | 67,078,184 |
| 价格/销量 (P/S) | 1.73 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -46.24% |
| 营业利益率 (TTM) | -56.88% |
| 稀释每股收益 (EPS TTM) | -1.53 |
| 季度收入增长率 (YOY) | 23.40% |
| 总债务/股东权益 (D/E MRQ) | 95.85% |
| 流动比率 (MRQ) | 1.52 |
| 营业现金流 (OCF TTM) | -8.74 M |
| 杠杆自由现金流 (LFCF TTM) | -5.06 M |
| 资产报酬率 (ROA TTM) | -50.68% |
| 股东权益报酬率 (ROE TTM) | -276.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | electroCore, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.3 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | -2.4 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.78 |
|
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 29.79% |
| 机构持股比例 | 18.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Jaffetilchin Investment Partners, Llc | 30 Jun 2026 | 59,954 |
该时间范围内无数据。
该时间范围内无数据。
投资组合